Webinars and Sponsored Roundtables — Register Now
Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Product Spotlight
Abbott
| Company | Abbott |
|---|---|
| Name of analyzer | Alinity h-series |
| Contact | James Pickering |
| City, State | Lake Forest, IL |
| Phone | 800-323-9100 |
| Website | |
| Analyzer application | diagnostic and research use |
| Dimensions of analyzer (H × W × | 59 × 24 × 36 in./— |
| Country where analyzer was | U.S./Singapore |
| First year analyzer was sold in U.S./Approximate No. of units installed in U.S.* | 2023/25 |
| First year analyzer sold outside | 2017/975 |
| Foreign locations where company | Brazil, Canada, Italy, Japan, Saudi Arabia, Spain, U.K., Vietnam, more (installed in the aforementioned countries) |
| Human languages (other than | Brazilian Portuguese, French, German, Italian, more |
| Analyzer list price | — |
| • Analyzer acquisition options | purchase, trade in, lease, reagent rental agreement |
| Training included with purchase/Total time for basic training per operator | 15 min. daily; 30 min. weekly |
| • Follow-up training available | yes (extra charge) |
| Parameters that analyzer tests and reports | %&# eosinophils, %&# immature granulocytes, %&# lymphocytes, %&# monocytes, %&# neutrophils, %&# basophils, %&# reticulocyte count, Hb, Hct, MCH, more |
| Types of testing FDA cleared or approved for analyzer | — |
| Types of body fluids FDA cleared or approved for analysis on analyzer | — |
| Analytical measurement range for body fluid | — |
| Precision for body fluid | — |
| Accuracy for body fluid | — |
| Automated differential performed for body fluids | — |
| Tests available for research use only | WBC viability fraction, % microcytic RBCs, % macrocytic RBCs, % hypochromic RBCs, % hyperchromic RBCs, more |
| Differential methods used | advanced MAPSS technology |
| Analytical measurement range: • WBC count/RBC count | WBC: 0.04–447.00 × 103 cells/µL/RBC: 0.01–8.08 × 106 cells/µL |
| Precision: • WBC count/RBC count | WBC: ≤3.5% CV @ >4.0 × 103 cells/µL/RBC: ≤1.5% CV @ >4.00 × 106 cells/µL |
| Accuracy: • WBC count/RBC count | — |
| Interfering substances: • WBC/RBC | cryoglobulin, cryofibrinogen, fragile WBCs, nonviable WBCs, neutrophil aggregates, hemoglobin C crystals, NRBCs, platelet clumps or aggregates/RBC autoagglutinins, cold agglutinins, giant platelets, RBC fragments |
| • Hemoglobin/Platelets | hemoglobin C crystals/RBC autoagglutinins, cold agglutinins, cryoglobulin, cryofibrinogen, giant platelets, platelet clumps or aggregates, platelet satellitism, RBC fragments, more |
| • Hematocrit/Reticulocytes | RBC autoagglutinins, cold agglutinins, giant platelets, platelet clumps or aggregates, more/RBC autoagglutinins, cold agglutinins, babesiosis, malaria, Heinz bodies, more |
| • Automated differential | cryoglobulin, cryofibrinogen, fragile WBCs, nonviable WBCs, neutrophil aggregates, hemoglobin C crystals, more |
| Throughput: max. CBCs per hour/Max. CBCs with differentials per hour | 119/119 |
| • Max. No. of slides processed per hour if stainer included | 65 |
| FDA-cleared or -approved sample container types (besides potassium EDTA) | none |
| Min. specimen volume open mode/Closed mode/Microsample capability | ≤100 µL/≤100 µL/no |
| Types of patient data archived/Max. No. of archived patient data accessible when analyzer online | patient demographics, previous test results, graphics, more (customizable)/— |
| Analyzer performs delta checks | yes |
| Parameters for which flags may appear | morphological flags, including left shift, blasts, variant lymphocytes, platelet clumps, RBC fragments, more |
| Analyzer recognizes and holds test results | yes, for follow-up, confirmatory testing, and potential test rerun (parameters for flags to hold samples defined by client or vendor) |
| Scattergram display uses cell-specific color | yes |
| Histogram display uses color with thresholds | yes |
| LIS interface formats supported | ASTM 1394-91, ASTM 1381, HL7 version 2, HL7 version 3 |
| • Middleware interface | yes (can use company’s middleware or third-party middleware or connect directly to LIS) |
| • Information transferred to LIS via middleware or LIS interface | numeric results, flagged results, histograms, scatterplots, patient demographics, patient orders, more |
| Analyzer transmits LOINC codes for results to LIS or middleware | no |
| Lab automation system or workcells to which analyzer has a direct interface | Abbott Diagnostics |
| Barcode symbologies read on specimen tube | Codabar, Code 39, Code 128, Interleaved 2 of 5 |
| • Analyzer allows barcode placement per CLSI standard Auto02-A2 | yes |
| No. of onboard reagents required for standard specimen analysis | 3 |
| • Reagents ready to use/Reagent tracking method | yes/barcode reader |
| Onboard diagnostics for troubleshooting | yes |
| • Manufacturer can perform diagnostics via remote access | yes |
| Warranty provided/Cost of annual service contract (24 h/7 d) | one-year warranty/variable |
| Notes | — |